Use of Pembrolizumab in End-Stage Renal Disease: A Case Report with Complete Response

Second-line treatment in urothelial carcinoma is not well defined. Immunotherapy has shown good outcomes in this setting, but it has not been tested in patients with end-stage renal disease (ESRD). We present a clinical case describing the use of pembrolizumab in a patient under hemodialysis (HD) th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitorino, Marina, Santos, Catarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958579/
https://www.ncbi.nlm.nih.gov/pubmed/35431871
http://dx.doi.org/10.1159/000521979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958579/
https://www.ncbi.nlm.nih.gov/pubmed/35431871
http://dx.doi.org/10.1159/000521979

Ejemplares similares